Last reviewed · How we verify
LM103
At a glance
| Generic name | LM103 |
|---|---|
| Sponsor | Suzhou BlueHorse Therapeutics Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- LM103 in Phase IIa Clinical Trial for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer (PHASE2)
- A Phase II Trial of LM103 in Advanced Melanoma (PHASE2)
- An Exploratory Clinical Study to Evaluate the Safety, Tolerability, Immune Response and Preliminary Efficacy of LM103 Injection in Combination With PD-1 in Patients With Advanced Solid Tumours (EARLY_PHASE1)
- A Clinical Study on LM103 Injection for the Treatment of Advanced Solid Tumors (EARLY_PHASE1)
- A Clinical Study on TILs for the Treatment of Advanced Solid Tumors (EARLY_PHASE1)
- A Clinical Study on LM103 for the Treatment of Advanced Solid Tumors (EARLY_PHASE1)
- A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LM103 CI brief — competitive landscape report
- LM103 updates RSS · CI watch RSS
- Suzhou BlueHorse Therapeutics Co., Ltd. portfolio CI